Antibody-Mediated Protection Against Symptomatic COVID-19 Can Be Achieved at Low Serum Neutralizing Titers

Investigators showed that a half-life–extended monoclonal antibody provided about 50% protection against symptomatic COVID-19 in SARS-CoV-2–naïve adults at serum neutralizing antibody titers on the order of 1:30.